It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hypoxia-Inducible Factor-1α (HIF-1α) has presented a new direction for ischemic preconditioning of surgical flaps to promote their survival. In a previous study, we demonstrated the effectiveness of HIF-1a DNA plasmids in this application. In this study, to avoid complications associated with plasmid use, we sought to express HIF-1α through mRNA transfection and determine its biological activity by measuring the upregulation of downstream angiogenic genes. We transfected six different HIF-1a mRNAs–one predominant, three variant, and two novel mutant isoforms–into primary human dermal fibroblasts using Lipofectamine, and assessed mRNA levels using RT-qPCR. At all time points examined after transfection (3, 6, and 10 h), the levels of HIF-1α transcript were significantly higher in all HIF-1α transfected cells relative to the control (all p < 0.05, unpaired Student’s T-test). Importantly, the expression of HIF-1α transcription response genes (VEGF, ANG-1, PGF, FLT1, and EDN1) was significantly higher in the cells transfected with all isoforms than with the control at six and/or ten hours post-transfection. All isoforms were transfected successfully into human fibroblast cells, resulting in the rapid upregulation of all five downstream angiogenic targets tested. These findings support the potential use of HIF-1α mRNA for protecting ischemic dermal flaps.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Johns Hopkins University School of Medicine, Department of Surgery, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Medical University of Lodz, Department of General and Oncological Surgery, Lodz, Poland (GRID:grid.8267.b) (ISNI:0000 0001 2165 3025)
2 Johns Hopkins University School of Medicine, Department of Surgery, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
3 Johns Hopkins University School of Medicine, Department of Surgery, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); University of Chicago Medicine, Department of Surgery, Chicago, USA (GRID:grid.170205.1) (ISNI:0000 0004 1936 7822)
4 Johns Hopkins University School of Medicine, Division of Thoracic Surgery, Department of Surgery, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)